Delivery Order HHSN271201500025I-HHSN27100007
Award Date
5/26/16
Potential Completion Date
9/14/20
Potential Value
$101K
Federal Agency
National Institute on Drug Abuse
Awardee
Pharmaron, Inc.
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Louisville, KY 40202, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health (NIH), to Pharmaron, Inc. for $149,520.00. The award is under the NIH Bioanalysis Testing Services 2015-2020 indefinite delivery/indefinite quantity (IDIQ) contract vehicle. Pharmaron, a minority-owned, for-profit contract research organization (CRO), will provide pharmacokinetics assessments, toxicity studies, and ion channel testing...
This is a federal contract award to Pharmaron, Inc., a global contract research organization (CRO) specializing in preclinical research services for the pharmaceutical and biotechnology industries, as well as government agencies. The contract was awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), and is part of the NIH Bioanalysis Testing Services 2015-2020 master indefinite-delivery, indefinite-quantity (IDIQ) contract. The contract...
This federal contract award is to Pharmaron, Inc., a global contract research organization (CRO) that provides preclinical research services for pharmaceutical and biotechnology companies, as well as government agencies. The contract, valued at $24,900, is a firm fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH). The award does not have a set-aside designation. Pharmaron, which is classified as a...
This is a firm fixed-price delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The $113,400 contract is part of the NIH Bioanalysis Testing Services 2015-2020 IDIQ (Indefinite Delivery/Indefinite Quantity) vehicle. The work involves conducting pharmacokinetic assessments, toxicity studies, and ion channel testing services to support drug discovery and development efforts, including evaluating...
This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute on Drug Abuse to Pharmaron, Inc., a global contract research organization. The $281,751.22 purchase order contract is for a firm fixed price and does not have a set-aside designation. Under this contract, Pharmaron is conducting a variety of drug development activities to support the work of the NIH's National Center for Advancing Translational Sciences...
This federal contract award to Pharmaron, Inc., a Minority Owned Business and For Profit Organization, was issued by the U.S. Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS). The contract, valued at $117,930.00, is a Firm Fixed Price Purchase Order to evaluate NNMT inhibitors in metabolic disorders. Pharmaron, a global contract research organization, will conduct various drug development activities...
This federal contract award, with a ceiling value of $1,927,163.66, was issued by the National Institute on Drug Abuse (NIDA), a component of the U.S. Department of Health and Human Services. The contract was awarded to SRI International, a non-profit research and development organization, and is part of NIDA's Pharmacology and Toxicology for Neurotherapeutics Program (PTNP). The contract, which is a Delivery Order under the PTNP Indefinite Delivery Vehicle (IDV), is for IND-enabling studies....
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $1,436,776 firm fixed price delivery order to Altasciences Clinical Kansas Inc. to conduct a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of an investigational agent from September 3, 2024 to March 2, 2026. This delivery order was issued against an existing $21 million single-award indefinite delivery contract with NIDA for pharmacokinetic and pharmacodynamic...
This federal contract award was issued by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a global contract research organization. The $87,805.00 firm fixed price contract was awarded as a delivery order under the NIH Bioanalysis Testing Services 2015-2020 master contract vehicle. Under this contract, Pharmaron conducted various drug development activities for NCATS, including...
This federal contract award was issued by the National Institute on Drug Abuse (NIDA), a civilian agency, to Quintara Discovery, Inc., a for-profit foreign-owned organization. The $85,942.00 Firm Fixed Price delivery order was made under the NIH Bioanalysis Testing Services 2015-2020 contract vehicle, with a period of performance ending on September 14, 2020. The contract did not have a set-aside designation. Quintara Discovery, Inc. is the prime contractor, and there is no information...